Autoimmune hemolytic anemia (AIHA) is a rare but clinically significant disorder in which the immune system mistakenly produces autoantibodies against red blood cells, leading to accelerated ...

Phase 2b LUMINA 2 study data support rilzabrutinib's FDA Breakthrough Therapy designation for the treatment of warm autoimmune hemolytic anemia. The Food and Drug Administration (FDA) has granted ...

Autoimmune Hemolytic Anemia: Types, Causes, Symptoms and Treatment: By Shreoshree Chakrabarty Autoimmune Hemolytic Anemia (AIHA) is a rare but serious type of anemia in which the immune system ...

Babesiosis, a tickborne zoonotic disease caused by intraerythrocytic protozoa of the genus babesia, is characterized by nonimmune hemolytic anemia that resolves with antimicrobial treatment and ...

Sanofi SNY announced that the FDA has granted Breakthrough Therapy designation to Wayrilz (rilzabrutinib), a novel oral, reversible Bruton’s tyrosine kinase (BTK) inhibitor, for the treatment of ...

Sanofi’s rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia Rilzabrutinib is the first and only investigational BTKi ...

Novartis AG (NYSE:NVS) released topline results on Tuesday from the VAYHIT2 Phase 3 trial evaluating ianalumab plus eltrombopag in patients with primary immune thrombocytopenia (ITP) previously ...

CAR T-cell therapies are now being used to treat patients with B-cell driven autoimmune diseases such as lupus. Another such condition is autoimmune hemolytic anemia, in which immune cells destroy red ...